Share this article
Share this article
BUENA, N.J., Feb. 16, 2021 /PRNewswire/ Teligent, Inc. (Nasdaq: TLGT), ( Teligent or the Company ), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries.
John Celentano, Chairman of Teligent s Board of Directors, commented on the appointment, stating that We are excited to have Bill join Teligent s Board of Directors. He is a strategic leader with extensive experience in helping businesses transform and achieve their potential. Following the strategic steps we announced earlier this year to strengthen the Company s balance sheet and position the business for success, we have reached a critical time in Teligent s journey where Bill s innovative thinking will b
Share this article
Share this article
MIAMI, Feb. 16, 2021 /PRNewswire/ After many years of research and input from millions of consultations, hear.com is excited to announce the launch of the
horizon hearing aid, the first hearing device designed exclusively for active, younger people. Founders
Dr. Marco Vietor and
Paul Crusius co-developed this unique, next-generation hearing device in partnership with German engineers from Signia, a top global hearing aid manufacturer.
Geared toward active baby boomers who want to improve their quality of life, the sleek, sexy and nearly invisible horizon hearing aids boast cutting-edge features and unparalleled power. This new device uses a unique speech-enhancing algorithm that is clinically proven to deliver better-than-normal hearing. In addition to Bluetooth connectivity and wireless, portable rechargeability that lasts up to 19 hours, horizon showcases two unprecedented, groundbreaking features controlled through a smartphone
Full Year and Fourth Quarter Highlights:
CVS Health logo (PRNewsFoto/CVS Health)
Full year total revenues increased to $268.7 billion, up 4.6% compared to prior year
Full year and fourth quarter GAAP diluted earnings per share from continuing operations of $5.47 and $0.75
Full year and fourth quarter Adjusted EPS of $7.50 and $1.30
Generated full year cash flow from operations of $15.9 billion
Results reflect COVID-19 impacts and related investments
2021 Full Year Guidance:
Adjusted EPS in the range of $7.39 to $7.55
Cash flow from operations in the range of $12.0 billion to $12.5 billion
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2020.
Aifred Health Named Top 3 Finalist in Global IBM Watson AI XPRIZE Competition
News provided by
Share this article
Share this article
MONTREAL, Feb. 16, 2021 /PRNewswire/ - Aifred Health announced today that the XPRIZE jury has selected Aifred Health as one of the 3 finalists for the IBM Watson AI XPRIZE. The company is competing for the grand prize of US$3.0 million which will be awarded in June, 2021, with 2nd and 3rd prize winners receiving US$1.0 million and US$0.5 million respectively.
Montreal-based Aifred Health was one of more than 700 applicants for this XPRIZE focused on employing AI to solve the world s grand challenges. Teams were judged by world-leading experts in AI who conducted extensive due diligence and reviews of each team s application and their ability to meet the key criteria of achieved technical impact; evidenced real-world impact; scalability of real-world impact; and ethics and safety.
Butterfly Network, a Global Leader in Democratizing Medical Imaging, Closes Business Combination and Will Begin Trading on the New York Stock Exchange Announces unaudited 2020 full-year revenue of at least $45 million, representing growth of at least 63%, each above prior forecast
News provided by
Share this article
GUILFORD, Conn. and NEW YORK, Feb. 16, 2021 /PRNewswire/
Butterfly Network, Inc. ( Butterfly or the Company ) (NYSE: BFLY), an innovative digital health company that is working to democratize medical imaging and contribute to the aspiration of global health equity, today announced that it has completed its business combination with Longview Acquisition Corp. (NYSE: LGVW.U, LGVW, LGVW WS) ( Longview ), a special purpose acquisition company sponsored by an affiliate of Glenview Capital Management, LLC ( Glenview ). The business combination, which was approved by Longview s stockholders at its special meeting held on February 12, 2021, will fuel further adopti